Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates

 Sub: Intimation under regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED With reference to the captioned subject, Please be noted that the board of directors at their meeting held on 04.01.2020 at 11:30 A.M. have taken the following items on record. 1. Incorporation of Two separate Subsidiaries of Shilpa Medicare Limited for Biologicals Division and Albumin Division It is further intimated that meeting commenced at 11:30 A.M. and ended at 12:00 Noon This is for your information and necessary records.
04-01-2020
Bigul

Shilpa Medicare Ltd - 530549 - Closure of Trading Window

 SUB: Closure Of Trading Window For Quarter Ended 31.12.2019 - Reg REF: Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015 Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED ****** Dear Sir, With reference to the above subject it is hereby informed that the trading window of Shilpa Medicare Limited will remain closed for dealing in the securities of the Company for all Designated Employees/ Persons and their immediate relatives with effect from 01st January, 2020 till the end of 48 hours from the declaration of the financial results for the third quarter ended 31st December, 2019. This is for your information and records. Thanking you,
27-12-2019
Bigul

Company news: Shilpa Medicare

 Shilpa Medicare on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its facility in Raichur, K
04-12-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549

 Shilpa Medicare Limited is pleased to announce successful closure of inspection, with the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India for the inspection conducted during the period 22nd July, 2019 to 26th July, 2019.
04-12-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Submission Of Related Party Transactions U/R 23(9) Of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2019.

 Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith enclosed Related Party Transactions on consolidated basis in the format as per the relevant Accounting Standards for the Half Year ended 30th September, 2019 Kindly take the same on record.
03-12-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kamal Kishore Innani
29-11-2019
Bigul

Shilpa Medicare Ltd - 530549 - Outcome of Board Meeting

 with reference to the captioned subject, please be noted that pursuant to the resolution passed at the meeting of the Board of Directors held on 09th September, 2019 at 10:30 AM for the following items. 1. Approval of the unaudited Financial Results (Standalone and Consolidated) for the quarter ended and six months ended 30th September, 2019, pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. the Statement of Financial Results along with the Statement of Assets and Liabilities, cash flow statements and limited review reports are enclosed as Annexure-I 2. Appointment of Mr. Piyush Goenka (DIN: 02117859) as an Additional Director of the Company in independent capacity with effect from 09.11.2019 based on the recommendation of Nomination and Remuneration Committee. the brief profile of Mr. Piyush Goenka is enclosed as Annexure -II
11-11-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - RESULTS FOR QUARTER AND HALF YEAR ENDED 30.09.2019

 With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 09th November, 2019 at 10:30 A.M. for the following items. 1. Approval of The unaudited Financial Results (Standalone and Consolidated) for the quarter ended and six months ended 30th September, 2019, pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The Statement of Financial Results along with Statement of Assets and Liabilities, Cash Flow Statements and Limited review reports are enclosed as Annexure-1. 2. Appointment of Mr. Piyush Goenka (DIN: 02117859) as an Additional Director of the Company in Independent capacity with effect from 09.11.2019 based on the recommendation of Nomination and Remuneration Committee. The brief profile of Mr. Piyush Goenka is enclosed as Annexure-II
09-11-2019
Bigul

SHILPA MEDICARE LTD. - 530549 - Intimation Of Outcome Of Board Meeting 09.11.2019

 With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 09th November, 2019 at 10:30 A.M. for the following items. 1. Approval of The unaudited Financial Results (Standalone and Consolidated) for the quarter ended and six months ended 30th September, 2019, pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The Statement of Financial Results along with Statement of Assets and Liabilities, Cash Flow Statements and Limited review reports are enclosed as Annexure-1. 2. Appointment of Mr. Piyush Goenka (DIN: 02117859) as an Additional Director of the Company in Independent capacity with effect from 09.11.2019 based on the recommendation of Nomination and Remuneration Committee. The brief profile of Mr. Piyush Goenka is enclosed as Annexure-II
09-11-2019
Bigul

Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549

 This is to inform you that the Company has received U.S Food and Drug Administration final approval for its ANDA, Erlotinib Tablets, 25 mg, 100 mg, and 150 mg on 05 Nov 2019. Erlotinib Tablets, 25 mg, 100 mg, and 150 mg is a generic equivalent of reference listed drug (RLD) TARCEVA used in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) and locally advanced, unresectable or metastatic pancreatic cancer as recommended in the label approved by FDA. According to IQVIA MAT Q2 2019 data, the US market for Erlotinib Tablets is approximately US$ 172 Million. This is for your information and doing the needful.
06-11-2019
Next Page
Close

Let's Open Free Demat Account